<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323635</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-000960</org_study_id>
    <nct_id>NCT00323635</nct_id>
  </id_info>
  <brief_title>A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.</brief_title>
  <official_title>A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare frequency of urination during the night when women take
      tolterodine tablets vs. when they take placebo tablets.

      We will also measure whether between these two treatment conditions there are any differences
      in women's sleep, mood and performance on cognitive tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From midlife onwards, about half of women complain of poor sleep quality. One possible reason
      might be an increased frequency of need to urinate during the night. Women feel more frequent
      urges to urinate when structures that support the bladder become more lax. Tolterodine is a
      drug that can raise the threshold for volume of urine that accumulates in the bladder before
      the urge to urinate arises.

      Many factors determine how people say they sleep, such as their sleep as recorded by
      sleep-measuring instruments, how closely they notice their night's sleep, whether they are
      generally prone to make positive or negative judgments or to have a lot or a few body
      symptoms.

      In this study, women between ages 45 to 65 who are past the menopause and who are frequently
      bothered by the need to urinate during the night will take either tolterodine or placebo
      tablets for 8 weeks. During the last week they will record the hours they slept and the
      quality of their sleep each morning. They will wear a device on their wrist through the week
      that continuously records whether they are asleep or awake. During three nights of the week
      they will record the volume of urine whenever they urinate. At the end of the week they will
      complete questionnaires about their mood and take some computerized tests that measure their
      alertness. Thereafter they will repeat these procedures, taking the kind of tablets they did
      not take during the first 8-week treatment period.

      We will compare the frequency of urination, sleep, mood as adjusted for the tendency to make
      positive or negative judgments and daytime attention level to find if any of these differ
      between the two treatment periods, and to explain differences between any differences that
      may be found.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New department chairman instructed PI to discontinue study.
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal Urinary Frequency, Recorded on an Event/Symptom Chart;</measure>
    <time_frame>2 months</time_frame>
    <description>Subjects note: 1. Number of nocturnal and diurnal voids; 2) level of urgency for 7 days, graded 1 to 4, beginning after the first void on the Friday morning of week 7 and week 13 of their participation; 3) Number of incontinence episodes; 4) Relationship of incontinence to urge or stress (4 grade scale); 4) Whether she used any pads.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urgency</measure>
    <time_frame>Beginning after the first void on the Friday morning of week 7 and week 13 of their participation;</time_frame>
    <description>Level of urgency for 7 days, graded 1 to 4,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Incontinence Episodes;</measure>
    <time_frame>Duration of Study</time_frame>
    <description>Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship of Incontinence to Urge or Stress</measure>
    <time_frame>Duration of study</time_frame>
    <description>4-grade scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological Self-reports, Scores on Anxiety and Depression Rating Scales;</measure>
    <time_frame>2 weeks</time_frame>
    <description>State and Trait scores on Spielberger State-Trait Anxiety Inventory; The score measured by the Zung Self-Rating Depression Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, Scores on the Women's Health Questionnaire.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Self-reported vasomotor symptoms, other somatic symptoms, anxiety, depression, sleep and cognitive symptoms (memory, concentration and clumsiness problems), measured as category scores. Subjective sleep onset and total sleep times measured as 7-day averaged minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>Two 20-minute sessions during 2 months</time_frame>
    <description>Motor speed (number of finger taps in 30 seconds); Continuous Performance (mean response time elicited by appearance of target alphabet letter presented in a series of letters on a monitor screen for 1 minute); Color-Word Stroop Test (response times to stimuli with congruent word and color)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperarousal</measure>
    <time_frame>At baseline and 8 weeks later</time_frame>
    <description>Score on 26-item self-report Hyperarousal Scale that indicates proportion of attention allocated to visceral-somatic information vs. external sensory data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether She Used Any Pads.</measure>
    <time_frame>Duration of Study</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pads Used</measure>
    <time_frame>Duration of Study</time_frame>
    <description>Pads used</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep / Wake Pattern</measure>
    <time_frame>Two weeks</time_frame>
    <description>Wrist actigraphy measures of total daytime and nighttime activity scored by standardized Actiwatch measures of sleep and sake.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolterodine 4 mg q.d. X 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolterodine</intervention_name>
    <description>tablet, 4 mg, daily, 1 month</description>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Detrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Post-menopausal women, age 45 to 65 years old.

          2. No menses for at least 6 months before the study start.

          3. Have at least 14 episodes of nocturia per week.

          4. Have at least 4 hot flashes daily.

          5. Overall good health, as evidenced by a letter from the primary care provider.

          6. Agree not to use exogenous hormones including soy isoflavones or soybean-based shakes,
             or nutritional supplements that potentially reduce hot flashes.

          7. Have discontinued all hormone treatments, systemic, topical, or vaginal, at least 60
             days before admission and throughout participation in the study.

        Exclusion Criteria:

          1. Use of anti-cholinergic, hypnotic or sedating drugs

          2. Presence of urinary retention, gastric retention, chronic severe constipation,or
             narrow-angled glaucoma.

          3. A urinary tract infection within a month of study start.

          4. Undiagnosed abnormal vaginal bleeding.

          5. Benign or malignant liver disease.

          6. History or presence of chronic alcoholism or medication addiction within the past 5
             yrs.

          7. An acute systemic infection within seven days before the study start.

          8. Concurrent participation in another clinical trial and/or receiving an experimental
             medication/device in the last 30 days before admission to the study.

          9. History of shift work within the past 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quentin R Regestein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Roehrs T, Merlotti L, Petrucelli N, Stepanski E, Roth T. Experimental sleep fragmentation. Sleep. 1994 Aug;17(5):438-43.</citation>
    <PMID>7991955</PMID>
  </reference>
  <reference>
    <citation>Shaver JL, Paulsen VM. Sleep, psychological distress, and somatic symptoms in perimenopausal women. Fam Pract Res J. 1993 Dec;13(4):373-84.</citation>
    <PMID>8285088</PMID>
  </reference>
  <reference>
    <citation>Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003 May 1;26(3):342-92. Review.</citation>
    <PMID>12749557</PMID>
  </reference>
  <reference>
    <citation>Brooks JO 3rd, Friedman L, Bliwise DL, Yesavage JA. Use of the wrist actigraph to study insomnia in older adults. Sleep. 1993 Feb;16(2):151-5.</citation>
    <PMID>8446835</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <results_first_submitted>August 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2014</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Quentin Rodney Regestein, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>nocturia</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>tolterodine</keyword>
  <keyword>sleep</keyword>
  <keyword>sleep disorder</keyword>
  <keyword>menopause</keyword>
  <keyword>midlife women</keyword>
  <keyword>psychological tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women 45 to 65 years old were mailed post-cards with the study telephone number and e-mail address. Subjects were assessed for eligibility. The PI determined eligibility based on the study criteria. Eligible subjects were informed about the study requirements, risks and benefits, and then required to read and sign a consent form.</recruitment_details>
      <pre_assignment_details>Placebo responders were excluded after one week.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tolterodine</title>
          <description>Tolterodine 4 mg q.d. X 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tolterodine</title>
          <description>Tolterodine 4 mg q.d. X 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="5.2"/>
                    <measurement group_id="B2" value="53" spread="5.2"/>
                    <measurement group_id="B3" value="52" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nocturnal Urinary Frequency, Recorded on an Event/Symptom Chart;</title>
        <description>Subjects note: 1. Number of nocturnal and diurnal voids; 2) level of urgency for 7 days, graded 1 to 4, beginning after the first void on the Friday morning of week 7 and week 13 of their participation; 3) Number of incontinence episodes; 4) Relationship of incontinence to urge or stress (4 grade scale); 4) Whether she used any pads.</description>
        <time_frame>2 months</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Urinary Frequency, Recorded on an Event/Symptom Chart;</title>
          <description>Subjects note: 1. Number of nocturnal and diurnal voids; 2) level of urgency for 7 days, graded 1 to 4, beginning after the first void on the Friday morning of week 7 and week 13 of their participation; 3) Number of incontinence episodes; 4) Relationship of incontinence to urge or stress (4 grade scale); 4) Whether she used any pads.</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urgency</title>
        <description>Level of urgency for 7 days, graded 1 to 4,</description>
        <time_frame>Beginning after the first void on the Friday morning of week 7 and week 13 of their participation;</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Urgency</title>
          <description>Level of urgency for 7 days, graded 1 to 4,</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Incontinence Episodes;</title>
        <description>Number</description>
        <time_frame>Duration of Study</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence Episodes;</title>
          <description>Number</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relationship of Incontinence to Urge or Stress</title>
        <description>4-grade scale</description>
        <time_frame>Duration of study</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of Incontinence to Urge or Stress</title>
          <description>4-grade scale</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychological Self-reports, Scores on Anxiety and Depression Rating Scales;</title>
        <description>State and Trait scores on Spielberger State-Trait Anxiety Inventory; The score measured by the Zung Self-Rating Depression Inventory.</description>
        <time_frame>2 weeks</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Psychological Self-reports, Scores on Anxiety and Depression Rating Scales;</title>
          <description>State and Trait scores on Spielberger State-Trait Anxiety Inventory; The score measured by the Zung Self-Rating Depression Inventory.</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, Scores on the Women's Health Questionnaire.</title>
        <description>Self-reported vasomotor symptoms, other somatic symptoms, anxiety, depression, sleep and cognitive symptoms (memory, concentration and clumsiness problems), measured as category scores. Subjective sleep onset and total sleep times measured as 7-day averaged minutes.</description>
        <time_frame>2 weeks</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life, Scores on the Women's Health Questionnaire.</title>
          <description>Self-reported vasomotor symptoms, other somatic symptoms, anxiety, depression, sleep and cognitive symptoms (memory, concentration and clumsiness problems), measured as category scores. Subjective sleep onset and total sleep times measured as 7-day averaged minutes.</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <time_frame>2 months</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function</title>
        <description>Motor speed (number of finger taps in 30 seconds); Continuous Performance (mean response time elicited by appearance of target alphabet letter presented in a series of letters on a monitor screen for 1 minute); Color-Word Stroop Test (response times to stimuli with congruent word and color)</description>
        <time_frame>Two 20-minute sessions during 2 months</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function</title>
          <description>Motor speed (number of finger taps in 30 seconds); Continuous Performance (mean response time elicited by appearance of target alphabet letter presented in a series of letters on a monitor screen for 1 minute); Color-Word Stroop Test (response times to stimuli with congruent word and color)</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperarousal</title>
        <description>Score on 26-item self-report Hyperarousal Scale that indicates proportion of attention allocated to visceral-somatic information vs. external sensory data.</description>
        <time_frame>At baseline and 8 weeks later</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperarousal</title>
          <description>Score on 26-item self-report Hyperarousal Scale that indicates proportion of attention allocated to visceral-somatic information vs. external sensory data.</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whether She Used Any Pads.</title>
        <description>Yes/No</description>
        <time_frame>Duration of Study</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Whether She Used Any Pads.</title>
          <description>Yes/No</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pads Used</title>
        <description>Pads used</description>
        <time_frame>Duration of Study</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
          </group>
        </group_list>
        <measure>
          <title>Pads Used</title>
          <description>Pads used</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sleep / Wake Pattern</title>
        <description>Wrist actigraphy measures of total daytime and nighttime activity scored by standardized Actiwatch measures of sleep and sake.</description>
        <time_frame>Two weeks</time_frame>
        <population>No data collected or analyzed for the outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolterodine</title>
            <description>Tolterodine 4 mg q.d. X 8 weeks
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
tolterodine: tablet, 4 mg, daily, 1 month</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep / Wake Pattern</title>
          <description>Wrist actigraphy measures of total daytime and nighttime activity scored by standardized Actiwatch measures of sleep and sake.</description>
          <population>No data collected or analyzed for the outcome measures.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <desc>Only serious adverse effects were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Tolterodine</title>
          <description>Tolterodine 4 mg q.d. X 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Dropout patient explained she had to go to hospital because of pneumonia. However, tt remained unclear whether she in fact had pneumonia.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quentin Regestein</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-4497</phone>
      <email>qregestein@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

